June 7, 2018
BioMarin bags $20 million in milestone payments
BioMarin Pharmaceutical has received $20 million in milestone payments from Pfizer Inc, it said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
June 7, 2018
Merck, 4D evaluating Keytruda + 4D’s oncology programme for patients with solid tumours
A clinical stage biopharmaceutical company, 4D pharma, pioneering the development of Live Biotherapeutic Products, has made a deal with a subsidiary of…
June 7, 2018
Study findings on mineral excipient for enhanced ODTs
In a recent study, scientists confirmed the ability of Omyapharm to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel and…
June 7, 2018
Allergan and actress Shay Mitchell join forces to inspire women to know their birth control
Allerganhas launched ‘BC Trivia’ featuring actress and new ambassador Shay Mitchell – a fun and engaging trivia quiz designed to…
June 6, 2018
Schreiner MediPharm develops smart blister pack for clinical trial
Schreiner MediPharm developed a smart blister pack for a multinational pharmaceutical corporation, for digital patient compliance monitoring to enhance medication…
June 6, 2018
Alkermes net $50 million from Biogen in connection with multiple sclerosis drug BIIB098
Alkermes has received a $50 million payment from Biogen after it reviewed the preliminary gastrointestinal tolerability data from the ongoing…
June 5, 2018
FDA approves Mylan’s drug that helps reduce the risk of infection during cancer treatment
The U.S. Food and Drug Administration has approved Mylan’s Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance…
June 4, 2018
Bayer plans closing of Monsanto acquisition on June 7
Bayer plans to complete the acquisition of Monsanto on June, 7, doubling the size of its agriculture business, the company…
June 4, 2018
Novartis to seek approval of Kisqali plus fulvestrant for postmenopausal women with advanced breast cancer
Novartis on Sunday announced positive results from the third Phase III trial of Kisqali in advanced or metastatic breast cancer.
June 4, 2018
FibroGen’s pamrevlumab+chemotherapy could be neoadjuvant treatment regimen for certain advanced pancreatic cancer
FibroGen, a biopharmaceutical company, on Monday said the results from the Phase 1/2 clinical trial, testing pamrevlumab in combination with…